Delisting of Pharmaceutical Patents Challenged by the Federal Trade Commission

This cohort study evaluates all products targeted by the Federal Trade Commission from 2023 to 2025 and analyzes how delistings have impacted periods of patent protection.

Corresponding Author: William B. Feldman, MD, DPhil, MPH, Division of Pulmonary, Critical Care, Sleep Medicine, Clinical Immunology, and Allergy, Department of Medicine, University of California, Los Angeles, 200 Medical Plaza, Ste 365, Los Angeles, CA 90095 (wfeldman@mednet.ucla.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.